Bristol Myers Squibb News

SUMMARY: Pegylated interferon lambda 1a , administered once-weekly or once every 2 weeks with or without daily ribavirin, demonstrated potent activity against hepatitis C virus in genotype 1 patients in a Phase 1b study to be presented this week at the 60th Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

An anonymous tipster watched Bristol and Bristol Township cops raid a home in the 900 block of Park Avenue on a drug bust Oct.

Bristol-Myers Squibb Company today announced that the FDA has approved a labeling update for REYATAZ A to include long-term data from the CASTLE Study.

BOSTON A Bristol-Myers Squibb drug used to treat hepatitis B kept viral load levels down more effectively than its competitor, according to study results announced by the company.

Nov 4, 2009 - Exelixis, Inc. announced today that thirteen abstracts related to the company's development candidates have been accepted for presentation at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held November 15-19 in Boston.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

BARACLUDE Demonstrated Greater Antiviral Efficacy Compared To Adefovir In New Study Of Chronic Hepatitis B Patients With Cirrhosis Bristol-Myers Squibb today announced 48-week data from an ongoing study of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir.

Amylin Pharmaceuticals got a triple dose of good news over the weekend. Individually, each update might not have amounted to much, but together they were good for a 10% pop in the company's shares yesterday.

Bristol-Myers Squibb today announced 48-week data from an ongoing study of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir.

Bristol-Myers Squibb has selected a third compound being developed under Albany Molecular Research Inc.'s proprietary research program for preclinical development.

PRINCETON, N.J. & SEATTLE - Bristol-Myers Squibb Company and ZymoGenetics, Inc. today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-nave hepatitis C virus patients.

Not unlike its products that turn ugly mixtures into purer products, Waters turned an ugly top line into an acceptable earnings growth in the third quarter.

The focus of AstraZeneca 's earnings report illustrates the nature of polar opposites with one-time gains and new drugs.

Main Category: Breast Cancer Also Included In: Clinical Trials / Drug Trials Article Date: 29 Oct 2009 - 2:00 PDT Despite a recent study finding that an increasing number of women who had cancer in one breast are opting to have the other breast removed, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Breast ...

There are some life experiences few will ever have. And as the oldest of nine children and CEO of a Fortune 500 company, John Lechleiter has a couple under his belt.

The Bristol Riverside Theatre beefs up its administrative side in anticipation of new artistic and community forays.

ZymoGenetics, Inc. today announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda and ribavirin in treatment-naive patients with chronic hepatitis C virus infection .

ZymoGenetics Inc. said Tuesday it started a midstage study on a potential hepatitis C treatment, triggering a $70 million payment from its partner, Bristol-Myers Squibb Co.

Sun Microsystems plans to eliminate 3,000 positions world-wide in the next 12 months, and Expedia expects to close a call center in Tacoma, Wash., leaving roughly half its 170 workers unemployed.

London's new festival of puppetry for adults is long overdue a ' so why do so few theatremakers realise what it can do for their craft? Model citizens ... The RSC's staging of Venus and Adonis, put on in collaboration with the Little Angel puppet company.